Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic on H(1) Antihistamines: A Randomized, Placebo-Controlled Study

ASTERIA I was a 40-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subcutaneous omalizumab as add-on therapy for 24 weeks in patients with chronic idiopathic urticaria/spontaneous urticaria (CIU/CSU) who remained symptomatic despite H(1) antihistamine...

Descripción completa

Detalles Bibliográficos
Autores principales: Saini, Sarbjit S, Bindslev-Jensen, Carsten, Maurer, Marcus, Grob, Jean-Jacques, Bülbül Baskan, Emel, Bradley, Mary S, Canvin, Janice, Rahmaoui, Abdelkader, Georgiou, Panayiotis, Alpan, Oral, Spector, Sheldon, Rosén, Karin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269803/
https://www.ncbi.nlm.nih.gov/pubmed/25046337
http://dx.doi.org/10.1038/jid.2014.306

Ejemplares similares

Ejemplares similares